ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced it will give a poster presentation at the annual Alzheimer’s Association International Conference (AAIC®) to be held July 31-August 4, 2022 at the San Diego Convention Center, San Diego California and online.

 

Poster presentation of study comparing oligomer selectivity of PMN310 to that of other amyloid-beta-directed antibodies

 

Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: “Distinguishing between amyloid-beta-directed antibodies: ability of PMN310 to target toxic oligomers despite competing species.” The poster describes the design and results of a study  wherein ProMIS’ lead therapeutic candidate PMN310 was compared to other amyloid-beta-directed antibodies for selectivity and ability to maintain interaction with toxic oligomers in the presence of competing monomers.  

 

Dr. Kaplan will deliver her poster presentation (P1-090) on July 31 from 12:30 – 2:15 PM local time in person at the San Diego Convention Center Exhibit Hall and online. Please consult the AAIC® website (https://alz.org/aaic/overview.asp) for any further updates. The poster presentation will be available on the ProMIS website (www.promisneurosciences.com) after the AAIC® closes on Aug 4, 2022.

 

AAIC® is the largest, most influential international meeting focused on advancing dementia science. The annual conference convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care community to share research discoveries supporting new methods of prevention, treatment and diagnosis of Alzheimer’s disease.

 

ProMIS Neurosciences’ lead therapeutic candidate, PMN310, is a monoclonal antibody for Alzheimer’s disease created with a novel, proprietary method for generating and developing antibodies that can uniquely and precisely target toxic forms of otherwise normal proteins. PMN310 selectively targets the toxic oligomeric species of amyloid-beta (Aß), a root cause of Alzheimer’s disease. Preclinical studies have shown that PMN310 demonstrates a high degree of binding to toxic oligomers as opposed to non-toxic forms of Aß, possessing greater selectivity versus other Aß-directed antibodies.

 

 ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platforms – ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

 

www.promisneurosciences.com

 

Twitter and LinkedIn

Hot this week

Athens shines as Europe’s Youth Entrepreneurship capital at Gen-E 2025 Festival

The heart of European youth entrepreneurship beat in Athens...

Diabeloop and SOOIL launch DBLG1 with Dana-i Pump in Germany, Distributed by Mediq

Diabeloop is pleased to announce the commercial availability of...

Israel Sanctions Human Rights Lawyers as Legal Pressure Mounts Worldwide

In a dramatic escalation of its efforts to counter...

Why did Matt Cameron leave Pearl Jam ?

🎸 Matt Cameron Exits Pearl Jam After 27 Years:...

Topics

Athens shines as Europe’s Youth Entrepreneurship capital at Gen-E 2025 Festival

The heart of European youth entrepreneurship beat in Athens...

Diabeloop and SOOIL launch DBLG1 with Dana-i Pump in Germany, Distributed by Mediq

Diabeloop is pleased to announce the commercial availability of...

Israel Sanctions Human Rights Lawyers as Legal Pressure Mounts Worldwide

In a dramatic escalation of its efforts to counter...

Why did Matt Cameron leave Pearl Jam ?

🎸 Matt Cameron Exits Pearl Jam After 27 Years:...

A Culture of Lies: How Israel’s Leadership Lost Gaza, Truth, and the Public

As Israeli Prime Minister Benjamin Netanyahu boarded a plane...

UK Bans Palestine Action: Journalists and Protesters Face Legal Minefield Under Terrorism Law

New anti-terror powers spark outrage over free speech, press...

Related Articles

Popular Categories

spot_imgspot_img